ABC of a Health Problem: Antibiotics, Bacteria and Carriers

Evolution of typhoid bacteria

ABC of a Health Problem: Antibiotics, Bacteria and Carriers


In a study published in the latest issue of Science (24 November, 2006), an international consortium from the Max-Planck Society, Wellcome Trust Institutes in Britain and Viet Nam, and the Institut Pasteur in France have elucidated the evolutionary history of Salmonella Typhi.

Typhi is the cause of typhoid fever, a disease that affects 21 million people and kills 200,000 every year. The results indicate that asymptomatic carriers played an essential role in the evolution and global transmission of Typhi. One prediction from this rediscovery of the importance of the carrier state is that treatment of acute disease, including vaccination, is not enough to eradicate this disease.

The results also illuminate patterns leading to antibiotic resistance after the indiscriminate use of antibiotics. Fluoroquinolone treatment in southern Asia over two decades has resulted in the emergence of multiple, independent, nalidixic acid-resistant mutants, of which one group, H58, has multiplied dramatically and spread globally. Resistant strains reduce effectiveness of treatment using antibiotics. The report also has broad implications for analysing other emerging diseases.

Typhoid fever remains a major health problem in the developing world and continues to cause disease in Europe and the Americas. The evolutionary history and population structure of Typhi were poorly understood, partly because these bacteria show little genetic diversity.

Lack of information about the population structure of S. Typhi has impeded efforts to understand the epidemiology of the disease and to bring it under control in poorer countries. A project to solve this problem was derived through discussions between Mark Achtman from the Max-Planck Institut für Infektionsbiologie, Berlin and Gordon Dougan at the Wellcome Trust Sanger Institute and was underpinned by a large grant from the Wellcome Trust that also supported Philippe Roumagnac, a key scientist on this project.

The teams combined their resources to assemble for the first time a globally representative collection of 105 strains of Typhi, and investigated the sequence diversity within 90,000 base pairs per strain. They detected 88 informative sequence differences, showing that the population structure has evolved over the last 10,000 to 43,000 years.

Amazingly, the ancestral strain continues to exist today, as do many of its direct descendents, indicating a neutral population structure, whereas normally selective forces lead to extinction of intermediate genotypes. Furthermore, these bacteria are distributed globally, demonstrating that Typhi has spread inter-continentally on multiple occasions.

The authors propose that the unusual population structure of Typhi reflects long-term carriage by asymptomatic carriers, who reached public notoriety at the beginning of the 20th century with "Mr. N the milker" in England and "Typhoid Mary" (Mary Mallon) in the USA. These individuals infected hundreds of people over the decades while they worked in the food production industry.

Similar, healthy carriers may have allowed Typhi to survive in hunter-gatherer populations prior to the Neolithic expansion of city states and facilitated its intercontinental spread. Healthy carriers are also consistent with the observation that individual genotypes of Typhi persist for many decades within each country.

Increasing resistance to antibiotics in recent decades has hampered efforts of clinicians to treat typhoid fever. The indiscriminate use of fluoroquinolones, which is a cost-effective, standard treatment for typhoid fever, has been accompanied by a frightening increase in the numbers of resistant Typhi. Investigations of a large strain collection from southern Asia revealed that many different genotypes independently acquired resistance to nalidixic acid, a fluoroquinolone. One of these genotypes, H58, has become predominant throughout southern Asia and has even spread to Africa.

In Viet Nam, up to 95 per cent of Typhi are now resistant to nalidixic acid and many other antibiotics. Although these cases can still be treated with newer antibiotics, those antibiotics are much more expensive than standard fluoroquinolones, which raises the cost of medical treatment. Furthermore, it is likely that Typhi will develop resistance to these antibiotics as well.

The combination of these investigations raises problems for public health measures. Indiscriminate antibiotic usage results in real-time evolution of bacteria that resist treatment. Furthermore, the healthy carrier state provides a safe reservoir for these bacteria which allows them to evade short-term antibiotic treatment and vaccination, indicating that typhoid fever will remain a major health problem for the foreseeable future.

Notes to Editors
  • Evolutionary history of Salmonella typhi.

    Roumagnac P, Weill FX, Dolecek C, Baker S, Brisse S et al.

    Science (New York, N.Y.) 2006;314;5803;1301-4

Project information

The research was carried out collaboratively by the Max-Planck Institut für Infektionsbiologie in Berlin, the Wellcome Trust Sanger Institute, Hinxton Hall, the Institut Pasteur, Paris, and the Oxford University Clinical Research Unit, Ho Chi Minh City, with assistance from hospitals in Ho Chi Minh City and Hanoi and the International Vaccine Institute in Seoul.

Financial support was by the Wellcome Trust, UK.

Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
CB10 1SA,

Mobile +44 (0) 7748 379849

Recent News

Appointments and changes to the Genome Research Limited Board
At the GRL Board meeting on 2 December 2019, David Willetts announced his intention to step down as Chair because of his extensive commitments across the academic and science sectors. Wellcome's Director, Jeremy Farrar, will take over the Chair of GRL Board from 1 January 2020.
Researchers identify new possibilities for the treatment of inflammatory bowel disease
Two molecular pathways found to be integral to maintaining balance in the digestive system
Root of childhood kidney cancer discovered
Pre-cancerous signatures found in healthy tissue point the way towards new treatment options